An investigational allogeneic T-cell immunotherapy for treating hematologic malignancies by replacing diseased blood and immune systems with purified regulatory T-cells, CD34+ stem cells, and conventional T-cells from matched donors.

An investigational allogeneic T-cell immunotherapy designed for hematologic malignancies in patients with haploidentical or partially matched donors, combining enriched CD34+ stem cells and specific T-cell subsets without requiring post-transplant cyclophosphamide.